Roche to acquire Carmot Therapeutics for $2.7 billion

This post was originally published on this site

ZURICH (Reuters) – Pharmaceutical giant Roche said on Monday it has entered into a definitive agreement to acquire Carmot Therapeutics, a US company based in Berkeley.

Roche will pay an upfront purchase price of $2.7 billion and will make additional milestone payments of up to $400 million, it said in a statement.